Based on our decades of research experience in protein ubiquitin and degradation, Degron team has designed and synthesized a unique molecular glue degrader (MGD) compound library from conceptual understanding of MGD properties. Degron discovers novel disease targets that can be degraded by its library MGDs, including those “undruggable” by traditional small molecule inhibitors or monoclonal antibodies, via phenotypic, proteomic and induced-proximity screens. Supported by established tools covering cell-based assays, biochemical and biophysical assays, and mouse genetics, Degron MGD-target biology is fully validated and moved to preclinical and clinical development, to treat cancer, inflammation, metabolic and other diseases. Degron also predicts potential MGD targets by analyzing its inhouse chemical and target database, and uncovers specific degraders of selected targets by screening its proprietary MGD library.